S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

TSE:MSL - Merus Labs International Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume21,975 shs
Average Volume476,228 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-905-7260995

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MSL News and Ratings via Email

Sign-up to receive the latest news and ratings for MSL and its competitors with MarketBeat's FREE daily newsletter.


Merus Labs International (TSE:MSL) Frequently Asked Questions

What is Merus Labs International's stock symbol?

Merus Labs International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MSL."

Has Merus Labs International been receiving favorable news coverage?

News headlines about MSL stock have trended somewhat negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merus Labs International earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Merus Labs International.

What other stocks do shareholders of Merus Labs International own?

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:
  • Michael S. Cloutier, Independent Chairman of the Board
  • Barry Fishman, Chief Executive Officer, Director
  • Michael Scott Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • Frank Rotmann, Vice President and Head of European Operations
  • Robert Bloch M.D., Director
  • Theresa Sheila Firestone, Independent Director
  • David D. Guebert CPA, Independent Director
  • Robert S. Pollock, Independent Director
  • Timothy G. Sorensen, Independent Director

How do I buy shares of Merus Labs International?

Shares of MSL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Merus Labs International's official website?

The official website for Merus Labs International is http://www.meruslabs.com/.

How can I contact Merus Labs International?

Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-7260995.


MarketBeat Community Rating for Merus Labs International (TSE MSL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  419
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe MSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel